Jecure Therapeutics Inc.
4757 Nexus Center Drive
About Jecure Therapeutics Inc.
Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of fatty liver disease, NASH, and fibrosis. Our scientific founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician scientist in hepatology. Jecure Therapeutics combines cutting-edge academic biology with deeply experienced pharma/biotech scientists who are dedicated to discovering novel and impactful therapeutics for the treatment of liver disease.
Founder: Ariel Feldstein
President and CEO: Jeffrey A. Stafford, PhD
CSO: James M. Veal, PhD
Please click here for Jecure Therapeutics' job opportunities.
5 articles about Jecure Therapeutics Inc.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
Genentech Acquires Jecure Therapeutics
Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Jecure Therapeutics Strengthens Management Team
Jecure Therapeutics announced that Gretchen Bain, Ph.D., has joined the company as its Vice President of Biology.
New SoCal Biotech Jecure Therapeutics Makes Debut and Will Take on NASH